Neurofibromatosis 1 (NF1), also known as von Recklinghausen disease, is an
autosomal dominant condition caused by mutations of the NF1 gene, which is
located at chromosome 17q11.2, NF1 is believed to be completely penetrant,
but substantial variability in expression of features occurs. Diagnosis of
NF1 is based on established clinical criteria. The presentation of many of
the clinical features is age dependent. The average life expectancy of pati
ents with NF1 is probably reduced by 10-15 years, and malignancy is the mos
t common cause of death. The prevalence of clinically diagnosed NF1 ranges
from 1/2,000 to 1/5,000 in most population-based studies, A wide variety of
NF1 mutations has been found in patients with NF1, but no frequently recur
ring mutation has been identified. Most studies have not found an obvious r
elation between particular NF1 mutations and the resulting clinical manifes
tations. The variability of the NF1 phenotype, even in individuals with the
same NF1 gene mutation, suggests that other factors are involved in determ
ining the clinical manifestations, but the nature of these factors has not
yet been determined. Laboratory testing for NF1 mutations is difficult. A p
rotein truncation test is commercially available, but its sensitivity, spec
ificity, and predictive value have not been established, No general, popula
tion-based molecular studies of NF1 mutations have been performed. At this
time, it appears that the benefits of population-based screening for clinic
al features of NF1 would not outweigh the costs of screening.